🏅 ISO 9001:2015 Certified Corporate Debt Syndication Desk
desk@creditcares.in Mumbai: +91 97699 99870 Kolkata: +91 98300 38870
Underwriting Disclosure Indicative interest rates (8.35%–9.25% p.a.) and moratorium structures are subject to external credit rating (BBB to AAA), security coverage (FACR/LTV), TEV viability, and final sanction by participating consortium banks. Preliminary credit screening takes 14–21 working days.
CREDITCARESOne Stop Financial Assistance
Apply (10-500 Cr)
Pharmaceutical Formulations & Bulk Drug API Capex (₹15 Cr to ₹200 Cr)

Term Debt Syndication for USFDA, WHO-GMP Pharma & API Manufacturing Units

Consortium term debt, cleanroom machinery finance, and PLI incentive synchronization for pharmaceutical formulations, bulk drugs, and sterile injectables.

Confidential Mandate Review Calculate DSCR & Amortization
Direct Answer / Underwriting Overview

How does project finance work for Pharma & API manufacturing units in India?

Pharma and API project finance in India provides ₹15 Crore to ₹200+ Crore in consortium term debt for setting up or modernizing greenfield and brownfield formulation units, fermentation plants, and API bulk drug facilities. Regulated under strict USFDA, WHO-GMP, and environmental ZLD standards, bank underwriting evaluates process chemistry feasibility, key starting material (KSM) supply contracts, Central PLI scheme eligibility, and average DSCR benchmarks of 1.30x to 1.40x.

Institutional Underwriting & Structuring Benchmarks

Comparative debt syndication matrix across 45+ Scheduled Commercial Banks for Term Debt Syndication for USFDA, WHO-GMP Pharma & API Manufacturing Units.

Underwriting MetricPSU Bank Consortium NormsPrivate Bank / NBFC NormsCreditCares Structuring Advantage
Mandate Range ₹20 Cr to ₹200 Cr Consortium Capex ₹15 Cr to ₹75 Cr Bilateral Line Multi-bank syndication combining term capex and raw material working capital
Debt-to-Equity Ratio 2:1 (67% Debt, 33% Promoter Equity) 1.5:1 (Higher equity demand) Recognition of capitalized R&D and pilot plant expenditure in equity contribution
Repayment Tenor 7 to 10 Years door-to-door 5 to 7 Years door-to-door 10-Year tenor structured around drug master file (DMF) approval timelines
Moratorium Period 18 to 24 Months (Civil + Validation batches) 12 to 18 Months maximum Extended moratorium covering regulatory inspection audits (USFDA/EU-GMP)
PLI Scheme Integration Treated as cash inflow only post-sanction Ignored in baseline debt sizing Escrow structuring that utilizes Central PLI milestone grants to accelerate principal amortization

Execution Architecture & Mandate Delivery

How CreditCares navigates multi-banking committees, technical appraisals, and compliance milestones.

Central PLI Scheme & KSM Synchronization
Aligning project investment milestones with the Central Government’s Production Linked Incentive (PLI) scheme for Key Starting Materials (KSMs) and APIs.
Cleanroom & HVAC Modular Line Financing
Structuring specialized machinery term loans for automated sterile fill-finish lines, isolators, and AHU air-handling systems meeting ISO Class 5 standards.
Zero Liquid Discharge (ZLD) Effluent Debt
Financing multiple-effect evaporators (MEE), biological treatment plants, and RO systems required for State Pollution Control Board environmental consent.
Composite Working Capital & LC Limits
Syndicating raw material import Letters of Credit (LC) and export packing credit (EPC) alongside term capex to ensure immediate liquidity upon commercial launch.

Credit Committee Bankability & Risk Mitigation

Why large-ticket applications fail at the Sanction Committee stage and how our desk immunizes your proposal:

Risk Factor 01 Regulatory Audit Failure Risk

Banks fear plant shutdown if USFDA or state regulators issue Warning Letters. We verify clean audit track records and QA/QC management credentials.

Risk Factor 02 KSM Price Volatility from Overseas Suppliers

Margin compression from active ingredient spikes is stress-tested in CMA projections to ensure minimum DSCR remains ≥ 1.25x under adverse scenarios.

Risk Factor 03 Environmental Clearance Delays (EC / CTE)

Disbursement of Phase-2 debt is strictly conditioned on receiving Consent to Establish (CTE). We ensure environmental consultant filings match bank covenants.

Frequently Asked Questions

Mandate & Syndication Inquiries

Can PLI scheme subsidies be factored into bank debt calculations? ▼
Yes. While banks will not substitute subsidy for promoter equity, PLI incentives can be modeled in cash-flow forecasts to demonstrate enhanced debt repayment capacity.
What is the required debt-service coverage ratio (DSCR) for pharma project loans? ▼
Most PSU consortium banks require a minimum average DSCR of 1.30x and an initial-year DSCR of not less than 1.15x following commercial production.
Does CreditCares assist in syndicating working capital for export-oriented pharma units? ▼
Yes. We syndicate comprehensive working capital facilities including Packing Credit in Foreign Currency (PCFC), Letter of Credit (LC), and Bank Guarantees (BG).
What technical documentation is needed for an API plant bank loan? ▼
Process flow diagrams, KSM mass balance calculations, hazardous chemical handling licenses, CTE from Pollution Control Board, and an empanelled chemical engineer TEV report.
Can debt be raised for expanding R&D laboratories and bio-equivalence centers? ▼
Yes. We structure term loans from ₹10 Cr to ₹50 Cr specifically for specialized analytical instruments, chromatography systems, and clinical trial infrastructure.
Confidential Corporate Mandate Desk

Syndicate Your Pharma or API Project Mandate

Submit your formulations, API, or PLI project mandate for an expert bankability review and term-sheet structuring.

Priority WhatsApp Desk (+91 98300 38870) Schedule Term-Sheet Consultation
✓ ISO 9001:2015 Certified Advisory ✓ 45+ PSU & Private Bank Consortium Network ✓ Strict Non-Disclosure Agreement (NDA)